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Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the time of the diagnosis on overall
survival in patients recently diagnosed with non-small cell lung cancer.
Materials and methods: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Süleyman
Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the medical oncology outpatient clinic.
Results: A total of 518 patients were evaluated, including 260 patients with squamous cell carcinoma, 207 patients with adenocarcinoma,
50 patients with non-small cell lung cancer-not otherwise specified, and 1 patient with large cell carcinoma. The average life expectancy
was found to be 11.50 ± 1.40 months in patients with squamous cell carcinoma, 12.60 ± 1.59 months in patients with adenocarcinoma,
and 8.70 ± 1.87 months in the other patients. The estimated 5-year relative survival rate for non-small cell lung cancer was 8% (7% for
men and 18% for women). In the multivariate analysis, sex being male (HR, 2.41; P < 0.001), a performance status >2 (HR, 1.70; P <
0.001), the stage of cancer (HR, 1.37; P = 0.045), the presence of bone or liver metastasis (HR, 1.44, P = 0.009, HR, 1.57; P = 0.016,
respectively), and the patient not having received radiotherapy (HR, 3.25; P < 0.001) or chemotherapy (HR, 1.85; P = 0.001) were
defined as statistically significant predictive factors that reduced the overall survival.
Conclusions: In this study, sex, stage, performance status, the presence of liver or bone metastases, and treatment had an effect on
overall survival.
Key words: Non-small cell lung cancer, survival, factors affecting survival

1. Introduction
Global evaluations show that the majority of deaths are
caused by noncommunicable diseases. In predictions
for the 21st century, cancer is expected to be the biggest
obstacle to decreasing mortality rates and increasing life
expectancy. According to the latest report published by
the IARC (International Agency for Research on Cancer)
based on the GLOBOCAN (Global Cancer Observatory)
2018 predictions, it was estimated that the global cancer
burden would rise to 18.1 million new cases and 9.6
million deaths in 2018. According to this report, with 2.1
million new cases of lung cancer (11.6% of total cases)
and 1.8 million deaths (18.4% of total cancer deaths), lung
cancer continues to be the leading cause of cancer-related
mortality and the most commonly diagnosed cancer in
both men and women [1].

According to the cancer statistics report published
by the Turkish Ministry of Health in 2014, tracheal,
bronchial, and lung cancer is the most common type of
cancer in men (21.1% (age-standardized mortality rate
52.5/100000)) and breast cancer is the most common type
of cancer in women (24.9% (age-standardized mortality
rate 43.0/100000)) in Turkey. According to this report,
lung cancer is usually diagnosed at late stages and distant
metastasis is observed in 52.7% of the patients at the time
of the diagnosis [2].
Although improvements in early diagnosis and
treatment with the hope of improving survival are
promising, studies in the last 30 years have shown that
the expected improvement in survival has not yet been
achieved [3]. The 5-year survival rate for lung cancer is
18% (15% for men and 21% for women). Only 16% of the
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patients are diagnosed when the cancer is at a localized
stage for which 5-year survival rate is 56% [4]. It has been
the aim of many studies to determine the prognostic
factors in order to better evaluate treatment efficacy and
determine treatment methods in order to improve survival
rates [5,6]. Ignoring these factors will prevent actual
therapeutic differences from being revealed.
This study aimed to investigate the effect of clinical
and pathological indicators on overall survival in recently
diagnosed NSCLC (non-small cell lung cancer) patients
and we believe that the standardization of these factors in
future studies will help determine the optimal treatment.
2. Materials and methods
2.1. Study design
This study was conducted as a retrospective cohort study
between 2018 and 2019. Approval was obtained for this
study (no. 214, dated December 13, 2018) from the Ethics
Committee of the Faculty of Medicine in Süleyman
Demirel University.
The study population consisted of non-small cell lung
cancer patients who were diagnosed at the Faculty of
Medicine at Isparta Süleyman Demirel University Hospital
and presented to the Medical Oncology Outpatient Clinic
between January 1, 2010 and December 31, 2017. Patient
file records were reviewed by the researchers. It was aimed
to study the entire population. Among a total of 568 lung
cancer patients who presented to the oncology unit and
received a pathological diagnosis, 518 patients (91.1%)
whose records could be accessed were included in the
study (Figure 1).
2.2. Data collection
Demographic data (age, sex, marital status, social security,
comorbidity, history of alcohol use, and smoking),
symptoms (presence of lung-related or non-pulmonary
symptoms), clinical (performance status), and followup (treatments administered after diagnosis, follow-up
duration, and overall survival rate, if any) information
of the patients, and information related to the disease
including the location of the tumor, histopathological
subtype, stage, and metastasis site, if any, were recorded
in the study.
2.3. Management of confounding variables
Age was evaluated as a continuous variable and according
to a cut-off point of 60 years. Considering the symptoms
of the patients at the time of the diagnosis, cough, sputum,
dyspnea, and bloody sputum were classified as pulmonary
symptoms, whereas numbness and pain in the body,
dysphagia, hoarseness, weakness, and night sweats were
classified as non-pulmonary symptoms. The patients were
grouped and analyzed according to the duration of their
symptoms being shorter or longer than 6 months and their
weight loss being more or less than 10%.

The patients’ smoking and drinking habits at the time
of the diagnosis were investigated and the pack-years
variable was used to evaluate smokers, while the exposure
variable was used to evaluate drinkers.
The presence of a second primary cancer in patients
was studied in 3 groups according to the presence of the
second primary cancer before, after, or concurrent with
lung cancer.
The performance status of the patients at the time of the
diagnosis was classified according to the ECOG (Eastern
Cooperative Oncology Group) scale of performance
status [7]. The treatments that the patients received
during follow-up were classified as surgery (palliativeradical), chemotherapy (CT; neoadjuvant, adjuvant and
palliative), radiotherapy (RT; palliative-curative), and
chemoradiotherapy (CRT).
The tumors were classified according to their
histological subtypes. Due to the ability of large-cell
carcinomas to represent weak or undifferentiated forms
of other cancers and the criteria for diagnosing large-cell
carcinomas being highly variable, this study focused on
squamous cell carcinoma and adenocarcinoma subtypes
of NSCLC. Cases of large cell carcinoma and NSCLC –
not otherwise specified – were combined and evaluated as
‘other types’. The cancer stage at the time of the diagnosis
was recorded. The pathologic stage was taken as a basis
in operated patients, while clinical staging was taken
as a basis in nonoperated patients. The American Joint
Committee on Cancer (AJCC) 8th edition TNM staging
system was used for staging the cancer [8]. Stage 1 and
stage 2 were combined due to the insufficient number of
patients. Stages 1a, 1b, 2a, and 2b were classified as ‘early’,
stages 3a, 3b, and 3c were classified as ‘locally advanced’,
and stages 4a and 4b were classified as ‘advanced stage’.
Localization, the location of metastasis (if any), the
date of pathologic diagnosis, and the diagnosis method of
the tumor were recorded from patient files.
The duration of patient follow-up at our clinic, the date
of pathological diagnosis, and the date of the last follow-up
appointment were determined. Records were made with
regard to the last follow-up appointment of the patient if
he/she was alive, the time of death if the patient had died,
and whether or not the death was related to lung cancer.
Overall survival was defined as the length of time from
the date of initial diagnosis to the date of file screening
(October 2018) for living patients, and as the length of
time from the date of initial diagnosis to the date of death
for deceased patients.
2.4. Statistical analysis
Statistical analyses were performed using a software
package. The effect of predisposing factors on survival was
calculated using the log-rank test and survival rates were
calculated using the Kaplan–Meier survival analysis. Using
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Figure 1. Number of patients admitted.

the possible factors identified in the previous analyses,
independent factors in predicting survival were examined
with the backward LR selection method using the Cox
regression analysis in the multivariate analysis. P < 0.05
was considered statistically significant.
3. Results
The mean age of the patients was 65.39 ± 9.39 years (min.
28 years – max. 87 years). Among the patients, 71.8% (n =
372) were 60 years and older at the time of the diagnosis,
and 88.6% (n = 459) of the patients were male. The most
common presenting symptoms were pulmonary symptoms
(62.7%) (n = 325) and the symptoms were generally present
for less than 6 months (80.1%). Moreover, 16.6% (n = 86)
of the patients had weight loss. The patients who had 10%
or more weight loss at the time of the diagnosis constituted
13.1% (n = 68) of the study population. Of the patients
with NSCLC, 84.6% (n = 438) had a history of smoking.
Patients who had a history of smoking more than 40 packyears constituted 62.4% (n = 323), while those who had
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a history of smoking less than 40 pack-years constituted
22.2% (n = 115) of the study population. Furthermore,
15% of the patients had a history of alcohol use and 47.7%
of the study population had a history of chronic disease
(Table 1).
A total of 518 patients who received a histopathological
diagnosis were evaluated. Of these patients, 260 (50.1%)
were diagnosed with squamous cell carcinoma, 207 (40%)
were diagnosed with adenocarcinoma, 50 (9.7%) were
diagnosed with NSCLC-NOS, and one patient (0.2%) was
diagnosed with large cell carcinoma. According to the
performance status of the patients measured when they first
presented to the hospital, 80.1% (n = 415) of the patients
had a performance status of 2 and below. There were 12
(2.3%) stage 1 patients, 57 (11.0%) stage 2 patients, 171
(33.0%) stage 3 patients, and 278 (53.7%) stage 4 patients.
Among the stage 4 patients, 97 patients had multiple organ
metastases. When metastatic localizations were analyzed,
the most common metastasis was found to be bone
metastasis which was present in 158 patients, followed
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Table 1: Demographic data of the patients.
NSCLC
n (row%)

Median survival
(Months) ± SE

P

<60

146 (28.2%)

17.97 ± 2.69

<0.001

≥60

372 (71.8%)

9.60 ± 0.79

Female

59 (11.4%)

23.50 ± 5.27

Male

459 (88.6%)

10.77 ± 0.95

Pulmonary

325 (62.7%)

15.83 ± 1.35

<0.001

Non-pulmonary

109 (21.1%)

8.40 ± 0.70

(Linear)

Both of them

84 (16.2%)

7.50 ± 0.95

<6 months

415 (80.1%)

11.70 ± 1.09

≥6 months

103 (19.9%)

12.23 ± 2.94

≥10%

68 (13.1%)

5.77 ± 0.81

<0.001

<10%

18 (3.5%)

9.80 ± 2.86

(Linear)

No

432 (83.4%)

13.80 ± 1.33

P < 40

115 (22.2%)

11.77 ± 2.13

P ≥ 40

323 (62.4%)

10.77 ± 0.95

No

80 (15.4%)

16.20 ± 3.05

Yes

79 (15.3%)

12.37 ± 2.32

No

439 (84.7%)

11.77 ± 1.10

Yes

247 (47.7%)

12.23 ± 1.88

No

271 (52.3%)

11.50 ± 1.12

Overall

518 (100%)

11.77 ± 1.00

Age at the time of diagnosis

Sex
0.004

Symptom

Symptom time
0.557

Weight loss
Yes

Smoking history
Yes
0.493

Alcohol history
0.366

Chronic disease

by liver metastasis in 53 patients, adrenal metastasis in 44
patients, contralateral lung metastasis in 43 patients, brain
metastasis in 40 patients, pleural-pericardial metastasis in
32 patients, and abdominal metastasis (other abdominal
organs except liver and adrenal) in 20 patients, respectively
(Table 2). The mean follow-up duration of the patients was
12.63 ± 15.45 months (min: 0–max: 95.83).
The patients were evaluated with the treatments they
received during follow-up. Since 123 patients were not
followed-up at our clinic (93 patients applied to another
medical center and 30 patients refused treatment), these
patients were analyzed as the group with unknown
treatment status when evaluating treatments. Considering

0.706

the surgical treatments, 62 patients underwent radical
and 10 patients underwent palliative surgery, while
323 patients did not receive surgical treatment and 123
patients were not followed-up at our clinic. Furthermore,
215 patients had received systemic CT. Among these
patients, 12 received neoadjuvant, 41 received adjuvant,
and 166 received palliative therapy. Since 4 patients
received neoadjuvant therapy followed by adjuvant
therapy, the group that received neoadjuvant and adjuvant
therapy consisted of 49 patients. Of the 42 patients who
received RT, 16 patients were given adjuvant RT and 26
patients were given curative RT. There were 95 patients
who received CRT treatment (Table 3).
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Table 2. Clinicopathological data of the patients.

NSCLC
Adenocarcinoma
Squamous
Other
ECOG
≤2
>2
Stage
1-2
3a
3b
3c
4a
4b
Metastasis
No
Single
≥2
Metastasis Location*
Bone met.
Yes
No
Liver
Yes
No
Brain
Yes
No
Adrenal
Yes
No
Contralateral Lung
Yes
No
Pleural/pericardial
Yes
No
Abdomen
Yes
No
Tumor localization
Right
Left
*Only metastasis group.
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NSCLC
n (row%)

Median survival
(months) ± SE

518
207 (40%)
260 (50.1%)
51 (9.9%)

11.77 ± 1.00
12.60 ± 1.59
11.50 ± 1.40
8.70 ± 1.87

415 (80.1%)
103 (19.9%)

15.90 ± 1.41
3.53 ± 0.63

69 (13.3%)
79 (15.2%)
76 (14.7%)
16 (3.1%)
181 (35.0%)
97 (18.7%)

44.47 ± 10.95
24.60 ± 3.09
16.27 ± 2.91
16.13 ± 4.53
8.07 ± 0.63
4.33 ± 0.42

240 (46.3%)
181 (35.0%)
97 (18.7%)

23.63 ± 1.50
8.07 ± 0.63
4.33 ± 0.42

<0.001
(Linear)

158 (56.8%)
120 (43.2%)

4.90 ± 0.75
8.07 ± 0.70

0.003

53 (19.1%)
225 (80.9%)

4.43 ± 0.50
7.70 ± 0.68

<0.001

40 (14.4%)
238 (85.6%)

4.33 ± 1.61
7.07 ± 0.55

0.762

44 (15.8%)
234 (84.2%)

5.57 ± 1.33
7.03 ± 0.59

0.148

43 (15.5%)
235 (84.5%)

8.40 ± 1.44
6.33 ± 0.62

0.552

32 (11.5%)
246 (88.5)

9.03 ± 1.41
6.20 ± 0.55

0.018

20 (7.2%)
258 (92.8%)

5.37 ± 1.57
7.03 ± 0.58

0.813

296 (57.2%)
222 (42.8%)

11.77 ± 1.34
11.47 ± 1.47

0.397

P
0.385

<0.001

<0.001
(Linear)
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Table 3: Treatment information of the patients.
NSCLC
n (row%)

Median survival
(months) ± SE

Radical Surgery

62 (12.0%)

68.94 ± 5.92*

Palliative Surgery

10 (1.9%)

7.53 ± 2.00

No Surgery

323 (62.4%)

12.03 ± 0.89

Unknown

123 (23.7%)

5.10 ± 0.74

Neoadjuvant/Adjuvant CT

49 (9.5%)

64.79 ± 6.98*

Palliative CT

166 (32.1%)

11.10 ± 0.94

Those who did not receive chemotherapy

180 (34.7%)

13.43 ± 1.63

Unknown group

123 (23.7%)

5.10 ± 0.74

Adjuvant RT

16 (3.1%)

45.50 ± 12.68

P

Surgery

<0.001**

Chemotherapy

<0.001***

Radiotherapy
Curative RT

26 (5.1%)

14.37 ± 3.05

Those who did not receive RT

353 (68.1%)

13.43 ± 1.27

Unknown group

123 (23.7%)

5.10 ± 0.74

Those who received CRT

95 (18.4%)

18.63 ± 1.84

Those who did not receive CRT

300 (57.9%)

12.20 ± 1.11

Unknown group

123 (23.7%)

5.10 ± 0.74

<0.001****

CRT
<0.001*****

*Mean (when median cannot be calculated).
**Difference:
1. A difference (P < 0.001, P < 0.001, P < 0.001, respectively) was found between the group that received radical
surgical treatment and the groups that received palliative surgical treatment, no surgical treatment and the unknown
group.
2. A difference (P < 0.001) was found between the unknown group and the group that did not receive surgical
treatment.
***Difference:
1. A difference (P < 0.001, P < 0.001, P < 0.001, respectively) was found between the group that received neoadjuvant/
adjuvant CT treatment and the group that received palliative CT, the group that did not receive CT and the unknown
group.
2. A difference (P < 0.001, P < 0.001, respectively) was found between the unknown group and the group that received
palliative CT and the group that did not receive CT.
****Difference:
1. A difference (P < 0.001, P = 0.001, P < 0.001, respectively) was found between the group that received adjuvant RT
and the groups that received curative RT, did not receive RT and the unknown group.
2. A difference (P < 0.001) was found between the group that did not receive RT treatment and the unknown group.
*****Difference:
1. A difference (P = 0.046) was found between the group that received CRT and the group that did not receive CRT.
2. A difference (P < 0.001, P < 0.001, respectively) was found between the unknown group and the group that received
CRT and the group that did not receive CRT.

3.1. Univariate survival analysis
The results of univariate analyses revealed that the patient’s
age being below 60 years (P < 0.001) and sex being female
(P = 0.004) significantly increased the survival time. When
the presence of symptoms at the time of the diagnosis

were ranked as pulmonary, nonpulmonary, and both,
and weight loss was ranked as none, less than 10%, and
more than 10%, the survival time was found to decrease
in proportion to the rank (linear P < 0.001, P < 0.001,
respectively) (Table 1).
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The median survival was found to be 11.77 ± 1.00
months in all patients diagnosed with NSCLC, with a
median life expectancy of 11.50 ± 1.40 months in patients
with squamous cell carcinoma, 12.60 ± 1.59 months in
patients with adenocarcinoma, and 8.70 ± 1.87 months in
other patients. The 5-year relative survival rate for NSCLC
was 8% (7% for men and 18% for women). No significant
difference was detected in terms of the survival time
between histopathological subtypes (Table 2).
The patient having an ECOG performance status above
2 at the time of the diagnosis significantly reduced the
survival time (P < 0.001). It was found that the survival time
significantly decreased with each stage increase (linear P
< 0.001). The analysis of the patients with no metastasis,
single metastasis, and multiple metastases revealed that
the survival times were significantly reduced in the same
order (linear P < 0.001) and that bone, liver, and pleuralpericardial metastases had a significant effect on survival
times (P = 0.003, P < 0.001, P = 0.018, respectively) (Table
2).
When the patients were evaluated according to the
treatments they received, it was found that the survival
times of the patients who received radical surgical
treatment was significantly longer than the patients who
received palliative surgical treatment and patients who
did not receive surgical treatment (P < 0.001, P < 0.001,
respectively). In terms of the CT treatment, it was observed
that the patients who received neoadjuvant/adjuvant CT
had significantly longer survival times than the patients
who received palliative CT and patients who did not
receive CT (P < 0.001, P < 0.001, respectively) (Table 3).
When the study population was evaluated in terms of RT
treatment, it was found that those who received adjuvant
RT treatment had longer survival times compared to the
patients who received palliative RT treatment and patients
who did not receive RT treatment (P < 0.001, P = 0.001,
respectively). The survival times of the patients who
received CRT treatment were significantly longer than the
patients who did not receive CRT treatment (P = 0.046)
(Table 3).
In order to better evaluate the effects of the treatments
received by the patients, the effect of the treatment on
survival was calculated using a separate log-rank analysis
by making a correction according to the stage of cancer.
The significantly high survival times in patients that
underwent radical surgery was also observed in the early
stage cancer and locally advanced cancer groups (Table 4).
Considering the chemotherapy treatment, it was
observed that in the locally advanced group, the patients
who received neoadjuvant/adjuvant CT treatment had
significantly longer survival times than the patients who
received palliative CT and patients who did not receive
CT treatment (P = 0.003, P < 0.001, respectively). In
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the metastatic cancer group, the patients who received
palliative CT treatment had significantly longer survival
times than the patients who did not receive CT treatment
(P < 0.001).
Evaluation of the RT treatment according to the
stages in all groups showed that the patients who received
adjuvant RT treatment had a significantly longer survival
time than the patients who received curative RT treatment,
while the patients who did not receive RT treatment had
a significantly longer survival time than the patients who
received curative RT treatment (P = 0.011, P = 0.012,
respectively). In addition, it was observed in the locally
advanced group that the patients who received adjuvant
RT treatment had a longer survival time than the patients
who did not receive RT treatment (P < 0.001) (Table 4).
The evaluation of the CRT treatment according to the
stages showed that there was no difference between the
patients who received CRT treatment and patients who
did not receive CRT treatment (Table 4).
3.2. Multivariate survival analysis
The Cox proportional hazards model was used in this
study to eliminate the complexity of and the interactions
between predictive values affecting survival and survival
times in lung cancer and to make the results more reliable.
The multivariate analysis included the parameters of
age, sex, the presence of symptoms, weight loss, ECOG
performance, stage, the presence of adrenal, bone,
pleural-pericardial, or liver metastases, whether or not the
patient received chemotherapy, radiotherapy, surgical, or
chemoradiotherapy treatment, which were found to be
significant in univariate analyses, which had a P value that
was close to a type 1 error value (with a cut-off value of P
= 0.25) and which had a correlation coefficient below 0.6
according to the matrix of regression coefficients.
In the multivariate analysis, male sex (HR, 2.4; P <
0.001), ECOG > 2 (HR, 1.70; P < 0.001), stage (HR, 1.37;
P = 0.045), the presence of bone or liver metastasis (HR,
1.44; P = 0.009, HR, 1.57; P = 0.016), and the patient
not having received radiotherapy (HR, 3.25; P < 0.001)
or chemotherapy (HR, 1.85; P = 0.001) treatment were
defined as statistically significant predictive factors that
reduced the overall survival. One unit of increase in the
stage of cancer (1-2/3a/3b/3c/4a/4b) increased the risk of
survival decrement by 1.367-fold (Table 5, Figure 2, Figure
3).
4. Discussion
According to the GLOBOCAN 2018 data, the 5-year
survival rate for lung cancer is 18% and only 16% of lung
cancer cases are diagnosed at an early stage. In this study,
the 5-year relative survival rate for NSCLC was 8% (7%
for men and 18% for women) and 13.3% of the patients
were diagnosed at an early stage (stage 1 and stage 2).
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Table 4: Kaplan–Meier Median Survival of the patients with non-small cell lung cancer (NSCLC) according to stage and treatment.
Early cancers
(stage 1-2)

Locally advanced
(stage 3)

Metastatic cancer
(stage 4)

Radical surgery

71.96 ± 7.27*

55.97 ± 8.78

-

Palliative surgery

-

18.43 ± 0.01

7.53 ± 2.93

No surgery

20.23 ± 3.99

17.70 ± 1.19

8.57 ± 0.62

24.57 ± 8.25

16.27 ± 3.34

3.60 ± 0.51

Neoadjuvant/Adjuvant CT

41.87 ± 12.06

71.42 ± 9.43*

-

Palliative CT

-

18.43 ± 8.41

10.77 ± 1.42

Those who did not receive CT treatment

58.50 ± 11.08

17.70 ± 1.25

7.99 ± 3.60

Unknown group

24.57 ± 8.25

16.27 ± 3.34

3.60 ± 0.51

Adjuvant RT

28.23 ± 2.24

45.50 ± 11.25

-

Curative RT

17.47 ± 3.54

14.36 ± 2.96

-

Those who did not receive RT treatment

63.57 ± 14.04

21.27 ± 2.74

8.10 ± 0.56

Unknown group

24.57 ± 8.25

16.27 ± 3.34

3.60 ± 0.51

Those who received CRT treatment

44.47 ± 17.08

18.63 ± 1.84

-

Those who did not receive CRT treatment

58.50 ± 6.55

24.03 ± 6.02

8.10 ± 0.56

Unknown group

24.57 ± 8.25

16.27 ± 3.34

3.60 ± 0.51

P

Surgery

Unknown group

<0.001**

Chemotherapy

<0.001***

Radiotherapy

<0.001****

CRT
<0.001*****

*Mean (when median cannot be calculated).
**Difference:
1. A difference (P <0.001) was found between the group that did not receive surgical treatment and the unknown group.
2. A difference (P = 0.001, P = 0.029, respectively) was found between the group that received radical surgical treatment and the group
that did not receive surgical treatment and the unknown group.
***Difference:
1. For the locally advanced group, a difference (P = 0.003, P < 0.001, P < 0.001, respectively) was found between the group that received
Neoadjuvant/Adjuvant CT treatment and the group that received palliative CT treatment, the group that did not receive CT treatment
and the unknown group.
2. For the metastatic cancer group, a difference (P < 0.001, P < 0.001, respectively) was found between the group that received palliative
CT treatment and the group that did not receive CT treatment.
****Difference:
1. A difference (P < 0.001) was found between the group that did not receive RT treatment and the unknown group.
2. A difference (P = 0.011, P = 0.012, respectively) was found between the group that received curative RT treatment and the group that
received adjuvant RT treatment and the group that did not receive RT treatment.
3. For the locally advanced group, a difference (P < 0.001, P = 0.018, respectively) was found between the group that received Adjuvant
RT treatment and the group that did not receive RT treatment and the unknown group.
*****Difference: A difference (P < 0.001, P < 0.001, respectively) was found between the unknown group and the group that did not
receive CRT treatment and the group that received CRT treatment.

The 5-year survival rate of patients diagnosed at an early
stage (stage1-2) was 34%, whereas the 5-year survival rate
of patients diagnosed at a locally advanced and advanced
stage (stage 3-4) was 5%. The low survival rates in this
study are due to the fact that 86.7% of our patients were
diagnosed at a locally advanced and advanced stage.
Survival rates in studies conducted with locally advanced

and advanced stage patients are similar to the survival
rates found in our study [1]. Wang et al. calculated the
5-year survival rate as 6.6% in their study conducted with
stage 3 and stage 4 NSCLC patients [9].
In this study, predictive values affecting survival
in patients with NSCLC were age, sex, the presence
of symptoms, weight loss, ECOG performance, stage,
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Table 5. Survival analysis for OS in non-small cell lung cancer.
Hazard Ratio

95% CI

P value

2.409

1.609–3.605

<0.001

> 2 versus ≤ 2

1.702

1.264–2.292

<0.001

Stage*(per 1 number increase)

1.367

1.006–1.857

0.045

1.444

1.097–1.900

0.009

1.569

1.088–2.262

0.016

3.251

2.378–4.445

<0.001

1.847

1.307–2.610

0.001

Covariates
Sex
Male versus female
ECOG

Bone met.
Yes versus No
Liver
Yes versus No
RT*(per 1 number increase)
Adjuvant RT/Curative RT/ RT not received/Unknown
CT*(per 1 number increase)
Neoadjuvant-Adjuvant CT/CT not received/Palliative CT/Unknown group

* linear
OS: overall survival
Method: Backward Stepwise (likelihood ratio): -2 Log likelihood: 2451.264; Omnibus test of model coefficients: P = 0.000.

Figure 2. Cox regression survival curves with the effect of cancer stage.

metastasis status, the presence of bone, pleural-pericardial,
and liver metastases, and chemotherapy, radiotherapy,
surgical, or chemoradiotherapy treatment status according
to the univariate analyses. Male sex, an ECOG value >2,
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increased stage, the presence of bone or liver metastasis,
and the patient not having received radiotherapy or chemo
radiotherapy treatment were defined as factors that decrease
overall survival according to the regression results.
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Figure 3. Cox regression survival curves with the effect of ECOG.

The results were significant in terms of the prediction
of outcomes and the effectiveness of the study population.
With one unit of increase in the stage of cancer
(1-2/3a/3b/3c/4a/4b), the risk increased significantly by
1.367-fold. In many studies conducted on both NSCLC
and SCLC, the stage of the disease is accepted as the most
important prognostic indicator for the determination of
survival [10–12].
Due to the fact that lung cancer survival rate
varies according to histological type and due to the
differential therapeutic efficacy and toxicity of newly
adapted therapies for NSCLC subtypes, a more precise
histological subtyping became necessary in order to use
the terms adenocarcinoma, squamous cell carcinoma,
and NSCLC-NOS [13,14]. Furthermore, the distribution
of the histological types and subtypes of microscopically
confirmed lung cancer varies between countries. In
general, the incidence of adenocarcinoma among men is
higher than that of squamous cell carcinoma. Histologyspecific survival is higher for adenocarcinoma and
squamous cell carcinoma than large cell carcinoma or
small cell lung cancer [15]. In our study, the survival time
for adenocarcinoma was found to be longer than that for
other types of cancer, which was similar to the literature
[16]. However, no difference was found between the
histological subtypes and this may be due to the subtypes
that could not be classified [17,18].
It was found that male had a 2.4-fold higher risk in
terms of overall survival and this finding is supported
by studies and meta-analyses conducted with patients

with NSCLC [11,19,20]. Radzikowska et al. have found
in their study conducted with 20,561 cases that low
ECOG performance (0-1 versus 3-4) was 2.58 times
riskier in terms of reduced survival [11]. In another study
examining stage 4 NSCLC patients, the risk was 1.9fold higher [21]. In this study, low performance status
affected the survival significantly and constituted a 1.7fold risk for overall survival. In addition, the effect of
ECOG and Cox regression survival curves provided in
Figure 3 shows that a worsening performance scale is
associated with poor survival. Performance status and
weight loss have been shown to be important prognostic
factors for NSCLC [12,22,23]. According to the univariate
analysis results in this study, weight loss at the time of
the diagnosis significantly reduced the survival time.
Although smoking status is a significant prognostic factor
for survival according to the literature, its effect could not
be shown in this study [24].
In our study, patients with single organ metastasis
had significantly longer survival times than patients with
multiple organ metastases, which is also supported in the
literature [25]. However, there are inconsistencies in the
literature about the sites of metastasis, with some studies
reporting that liver or adrenal metastasis is worse, and
others reporting that bone metastasis is worse [25,26].
For this reason, among the metastasis status (nonesingle-multiple) and metastasis sites that showed a high
correlation, we deemed it appropriate to include the
metastasis sites in the multivariate analyses conducted in
our study. According to the regression analysis, bone and
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liver metastases were 1.4 and 1.6 times riskier in terms
of survival, respectively. Bone metastasis is believed to be
associated with survival in addition to the pathological
processes related to the skeletal system such as pathological
fractures and hypercalcemia [27]. Metastatic liver lesions
are rarely associated with severe symptoms, but it is
known that most NSCLC patients with liver metastasis
do not respond well to chemotherapy [28,29]. Finkelstein
et al. described bone and liver metastases as independent
prognostic factors in 893 metastatic NSCLC patients
[30], while Tomohiro et al. supported the negative effects
of liver and adrenal gland metastasis on survival with
multivariate analysis results [26]. This study also showed
that bone and liver metastases were prognostic factors
which significantly short survival time in both univariate
and multivariate analysis results.
Surgical resection, if possible, remains to be the
most consistent and successful option for treatment in
patients with NSCLC and provides a chance for long-term
survival [31]. The survival time of the patients, who were
diagnosed at an early and locally advanced stage and were
able to undergo radical surgery, was significantly longer
in this study. This result may be remarkable in terms of
showing the effect of radical surgical treatment in patients
with locally advanced lung cancer.
Most of the phase 3 studies have shown that systemic
chemotherapy is superior to the best supportive care in
locally advanced and metastatic lung cancer patients [32].
Some meta-analyses have also supported that CT treatment
in advanced NSCLC patients provides improved survival
compared to supportive care [33–35]. It was found in this
study that advanced stage patients who received palliative
CT treatment had a significantly longer survival time than
those who did not receive CT treatment. In addition, the
efficacy of CT treatment was also significant according to
the results of further analyses.
The first major research on the role of RT in the
treatment of lung cancer was conducted by the Veterans

Administration Lung Study Group, wherein RT and
placebo groups were compared among patients with small
cell and non-small cell lung cancer, and higher survival
rates were found in patients who received RT treatment
[36,37]. In both the univariate and advanced analyses
performed in this study, the patients who did not receive
RT treatment were found to have a 2.45-fold higher risk
in terms of overall survival compared to the patients who
received adjuvant RT and curative RT.
Studies have shown that CRT treatment improves
survival in patients with non-small cell lung cancer
[38,39]. In this study, the efficacy of CRT was observed in
the univariate analyses that were performed, but the same
effect could not be demonstrated in advanced analyses.
The survival times of the patients who did not receive
CT treatment, RT treatment, and CRT treatment at an
early stage were longer than those of the patients who
received these treatments. This is due to the fact that
the patient group that did not receive CT treatment also
encompassed the group that received other treatments
(e.g., RT, surgery, CRT). Additionally, this study does not
include comprehensive information such as treatment
protocols and laboratory tests since it was not designed to
evaluate the effect of treatment on patients with NSCLC.
In conclusion, a median survival of 11.77 ± 1.00 months
and a 5-year relative survival rate of 8% were found in this
study for patients diagnosed with NSCLC. Univariate
analyses revealed that the patient’s age, sex, weight loss, the
presence of pulmonary and non-pulmonary symptoms,
performance scale, stage, metastasis status (none-singlemultiple), bone, liver, and pleural-pericardial metastasis
and treatments (surgery, CT, RT, CRT) were prognostic
factors that significantly affected the survival time. Sex,
stage, performance status, the presence of liver or bone
metastasis, and RT and CT treatments were shown to
have an effect on overall survival in multivariate analysis.
Further intervention studies are needed for the variables
determined as a result of multivariate analysis.
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